AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33072399 — intervention group
Group type: EXPERIMENTAL
Intervention: Early economic analysis
Number of subjects: 2
Study 33072620 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 0
Study 33072799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked Broccoli
Number of subjects: 0
Study 33072814 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose methylprednisolone (MP)
Number of subjects: 173
Study 33072814 — intervention group
Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 173
Study 33072885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 169
Study 33072885 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 169
Study 33073219 — intervention group
Group type: EXPERIMENTAL
Intervention: rBCG-N-RSV vaccine
Number of subjects: 0
Study 33073219 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 33073527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus original chemotherapy regimen
Number of subjects: 0
Study 33073527 — intervention group
Group type: COMPARATOR
Intervention: Original chemotherapy regimen
Number of subjects: 0
Study 33073557 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 biobank established with 46,677 samples collected from participants.
Number of subjects: 913
Study 33073614 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD implant
Number of subjects: 1111
Study 33073631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) for one hour
Number of subjects: 54
Study 33074097 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional diet in Mer
Number of subjects: 0
Study 33074097 — intervention group
Group type: COMPARATOR
Intervention: Access to takeaway food and alcohol in Waiben
Number of subjects: 0
Study 33074164 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements on social media websites (Facebook, Instagram, Twitter)
Number of subjects: 400
Study 33074164 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements on dating apps (Grindr, Jack'd, Hornet)
Number of subjects: 400
Study 33074164 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisements on informational websites (Google, Yahoo, Bing)
Number of subjects: 400
Study 33074330 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected children (H3N2)
Number of subjects: 44
Study 33074330 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccination (IIV)
Number of subjects: 44
Study 33074373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection or vitreoretinal surgery with incision distance of 3.5-4.0 mm posterior to the limbus.
Number of subjects: 200
Study 33074373 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended incision distance of 4.0 mm for AL > 25 mm.
Number of subjects: 200
Study 33074373 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended incision distance of 3.5 mm for AL < 22.5 mm.
Number of subjects: 200
Study 33074401 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat 10 mg twice daily
Number of subjects: 1
Study 33074401 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of an atypical tumor
Number of subjects: 1
Study 33074406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with pressure control/assist mode
Number of subjects: 100
Study 33074406 — intervention group
Group type: EXPERIMENTAL
Intervention: Datasets with ineffective triggering
Number of subjects: 100
Study 33074406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of opioids and sedatives
Number of subjects: 100
Study 33074406 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ineffective triggering
Number of subjects: 100
Study 33074470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic Hepatitis (AH)
Number of subjects: 131
Study 33074566 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature rGEV based on noncontrast-enhanced CT images
Number of subjects: 161
Study 33074566 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature rHRV based on noncontrast-enhanced CT images
Number of subjects: 161
Study 33074703 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 33074703 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance fluids, nutritional fluids, drug fluids
Number of subjects: 241
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics or renal replacement therapy
Number of subjects: 241
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium administration
Number of subjects: 241
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium administration
Number of subjects: 241
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid loss
Number of subjects: 241
Study 33074941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 90 days
Number of subjects: 241
Study 33075061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Germanium
Number of subjects: 130
Study 33075061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 33075126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) in ACS patients
Number of subjects: 5782
Study 33075126 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT) in ACS patients
Number of subjects: 5782
Study 33075126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) in SIHD patients
Number of subjects: 5782
Study 33075126 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (SAPT) in SIHD patients
Number of subjects: 5782
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and adapting recruitment methods
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible research team
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of transportation
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular information about the progress of the study
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low staff turnover
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility in appointment making
Number of subjects: 50
Study 33075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of appreciation by staff (letters, gifts, cards)
Number of subjects: 50
Study 33075149 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (original dose)
Number of subjects: 366
Study 33075149 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (individualised dose)
Number of subjects: 366
Study 33075149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil counts (first cycle)
Number of subjects: 366
Study 33075159 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 61
Study 33075159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral repaglinide
Number of subjects: 61
Study 33075159 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 61
Study 33075159 — intervention group
Group type: COMPARATOR
Intervention: Long-acting insulin glargine
Number of subjects: 61
Study 33075344 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels in compensated ACLD (cACLD) patients
Number of subjects: 168
Study 33075344 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels in decompensated ACLD (dACLD) patients
Number of subjects: 168
Study 33075344 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score across all stages of ACLD
Number of subjects: 168
Study 33075344 — intervention group
Group type: EXPERIMENTAL
Intervention: HVPG measurement in compensated ACLD patients
Number of subjects: 168
Study 33075344 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels across decompensated ACLD stages
Number of subjects: 168
Study 33076864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept intravitreal injection
Number of subjects: 20
Study 33076939 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 U/kg, administered intravenously within 72 hours of birth and then once every other day for 2 weeks)
Number of subjects: 1898
Study 33076939 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 U/kg)
Number of subjects: 1898
Study 33076939 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 1898
Study 33076994 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with ASD
Number of subjects: 162
Study 33076994 — intervention group
Group type: COMPARATOR
Intervention: TD participants
Number of subjects: 162
Study 33077004 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted gown and glove use during high-risk care activities
Number of subjects: 322
Study 33077273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment
Number of subjects: 294
Study 33077562 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography
Number of subjects: 2200
Study 33077562 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler acquisition
Number of subjects: 2200
Study 33077658 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam 2 grams
Number of subjects: 0
Study 33077867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (IC)
Number of subjects: 3637
Study 33077867 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intensive treatment
Number of subjects: 3637
Study 33077867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial (CT)
Number of subjects: 3637
Study 33077867 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care only (SC)
Number of subjects: 3637
Study 33077867 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (IC) in 2007-2013 vs 1999-2006
Number of subjects: 3637
Study 33077867 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (SC) in 2007-2013 vs 1999-2006
Number of subjects: 3637
Study 33078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 391
Study 33078076 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risks analysis considering death as a competing event
Number of subjects: 391
Study 33078240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power estimations
Number of subjects: 0
Study 33078240 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33078373 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin fixation of tumor specimens after infusion of panitumumab-IRDye800CW (25 or 50 mg)
Number of subjects: 30
Study 33078373 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-fixed specimens
Number of subjects: 30
Study 33078867 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab
Number of subjects: 60997
Study 33078867 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 60997
Study 33078998 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI
Number of subjects: 45
Study 33078998 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 45
Study 33078998 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 45
Study 33079066 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS program (intervention) involving peer modeling, parent engagement, and structured skills-based activities
Number of subjects: 72
Study 33079066 — intervention group
Group type: COMPARATOR
Intervention: Unstructured physical activity (comparator) curriculum providing suggestions for child-led physical activity (free play)
Number of subjects: 72
Study 33079066 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS program (intervention)
Number of subjects: 72
Study 33079066 — intervention group
Group type: COMPARATOR
Intervention: Unstructured physical activity (comparator) curriculum
Number of subjects: 72
Study 33079068 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL) yes
Number of subjects: 20
Study 33079068 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement System (MES) yes
Number of subjects: 20
Study 33079068 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders yes
Number of subjects: 20
Study 33079068 — intervention group
Group type: COMPARATOR
Intervention: Question Prompt List (QPL) no
Number of subjects: 20
Study 33079068 — intervention group
Group type: COMPARATOR
Intervention: Motivation Enhancement System (MES) no
Number of subjects: 20
Study 33079068 — intervention group
Group type: COMPARATOR
Intervention: Text message reminders no
Number of subjects: 20
Study 33079071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nod smartphone app (experimental group, n=100)
Number of subjects: 221
Study 33079071 — intervention group
Group type: COMPARATOR
Intervention: Control group (access after 4 weeks, n=121)
Number of subjects: 221
Study 33079259 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosarcopenic obesity (OSO)
Number of subjects: 460
Study 33079259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower handgrip strength
Number of subjects: 460
Study 33079259 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicular lean mass index (ALMi)
Number of subjects: 460
Study 33079259 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed
Number of subjects: 460
Study 33079376 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 62
Study 33079774 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately disproportioned GAP score category
Number of subjects: 159
Study 33079774 — intervention group
Group type: COMPARATOR
Intervention: Higher GAP score
Number of subjects: 159
Study 33079873 — intervention group
Group type: EXPERIMENTAL
Intervention: Recirculatory model
Number of subjects: 30
Study 33079873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated recurrent unit neural network with ensemble learning
Number of subjects: 30
Study 33079873 — intervention group
Group type: COMPARATOR
Intervention: 4-compartment model
Number of subjects: 30
Study 33079880 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Gastro™
Number of subjects: 30
Study 33080003 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC-ACS lesions
Number of subjects: 170
Study 33080003 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cells in disturbed laminar flow conditions
Number of subjects: 170
Study 33080003 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T cells and their cytotoxic effector molecules
Number of subjects: 170
Study 33080007 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry using the ΔN technique
Number of subjects: 784
Study 33080007 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic definition of persistent disease (>15% AML)
Number of subjects: 784
Study 33080007 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not achieving morphologic remission (>5% blasts)
Number of subjects: 784
Study 33080007 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔN technique
Number of subjects: 784
Study 33080007 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of abnormal myeloid progenitor cells by ΔN
Number of subjects: 784
Study 33080806 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 46
Study 33080806 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 33080911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as second-line therapy
Number of subjects: 76
Study 33080911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as third-line therapy
Number of subjects: 76
Study 33080911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine (T-DM1) as fourth-line therapy or higher
Number of subjects: 76
Study 33081973 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity less than two flights of stairs
Number of subjects: 4560
Study 33081973 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported functional capacity plus revised cardiac risk index (RCRI)
Number of subjects: 4560
Study 33082173 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed diabetes (NDD)
Number of subjects: 3501
Study 33082173 — intervention group
Group type: COMPARATOR
Intervention: Established diabetes
Number of subjects: 3501
Study 33082173 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 3501
Study 33082193 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI measured by VOPITB
Number of subjects: 120
Study 33082193 — intervention group
Group type: COMPARATOR
Intervention: CAVI measured by VaSera VS-1500
Number of subjects: 120
Study 33082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0
Study 33082208 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study 33082311 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breaths
Number of subjects: 440
Study 33082311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursts
Number of subjects: 440
Study 33082372 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) therapy, duration shortened in 11 of the 29 patients (38%)
Number of subjects: 29
Study 33082372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir for 6 weeks
Number of subjects: 29
Study 33083026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26 vector-based vaccine (Ad26.COV2.S)
Number of subjects: 0
Study 33083026 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33083050 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term perfluoro-n-octane (PFO) with perfluoropropane (C3F8) gas
Number of subjects: 30
Study 33083561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin as adjunctive therapy
Number of subjects: 0
Study 33083661 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT) reirradiation
Number of subjects: 45
Study 33083661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior surgery
Number of subjects: 45
Study 33083685 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, real-time activity-monitoring devices combined with daily electronic patient-reported outcome (ePRO) items.
Number of subjects: 80
Study 33083685 — intervention group
Group type: COMPARATOR
Intervention: Standard HF assessment (e.g., 6-min walking distance [6MWD], blood biomarkers, Kansas City Cardiomyopathy Questionnaire [KCCQ], and echocardiography).
Number of subjects: 80
Study 33083813 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (Reveal XT, Reveal Linq) implanted before hospital discharge with continuous monitoring for up to 2 years.
Number of subjects: 103
Study 33083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Group 1)
Number of subjects: 83
Study 33083823 — intervention group
Group type: COMPARATOR
Intervention: Non-operated women (Group 2)
Number of subjects: 83
Study 33083823 — intervention group
Group type: COMPARATOR
Intervention: Non-operated severely obese women (Group 3)
Number of subjects: 83
Study 33083853 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 lx drug-coated balloon
Number of subjects: 877
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-FT-derived remote circumferential strain (CS)
Number of subjects: 1034
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: RM CS cutoff value of -25.8%
Number of subjects: 1034
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired RM CS
Number of subjects: 1034
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: RM CS in patients with reduced LVEF ≤ 35%
Number of subjects: 1034
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: RM CS in patients with reduced GCS > -18.3%
Number of subjects: 1034
Study 33083869 — intervention group
Group type: EXPERIMENTAL
Intervention: RM CS in patients with large microvascular obstruction ≥ 1.46%
Number of subjects: 1034
Study 33084020 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing chemotherapy regimens
Number of subjects: 1349
Study 33084020 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum chemotherapy regimens
Number of subjects: 1349
Study 33084175 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 88
Study 33084183 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 0
Study 33084502 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent (DES)
Number of subjects: 0
Study 33084588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-Community-Family-Based Telemedicine (HCFT-AF) program
Number of subjects: 73
Study 33084880 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide, 5 mg daily for 16 weeks
Number of subjects: 240
Study 33084880 — intervention group
Group type: COMPARATOR
Intervention: Control group (AA genotype of the SNP rs13333226)
Number of subjects: 240
Study 33084880 — intervention group
Group type: COMPARATOR
Intervention: Control group (G allele)
Number of subjects: 240
Study 33085593 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic eye drops from cord blood platelet lysate (CBED), 1-2 drops to the affected eye four to six times per day for 19 days, median of 19 vials (range 19-442).
Number of subjects: 33
Study 33085815 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroRNAs (miRNAs)
Number of subjects: 0
Study 33085815 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type lectin receptors (CLRs)
Number of subjects: 0
Study 33085860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus glucocorticoids followed by two cycles of blinatumomab
Number of subjects: 63
Study 33086159 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus standard-of-care (SOC)
Number of subjects: 0
Study 33086159 — intervention group
Group type: COMPARATOR
Intervention: standard-of-care (SOC)
Number of subjects: 0